Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Business Wire
– New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24 –– Additional secondary endpoints show significant increases in days off PS and clinical responder rates with apraglutide, including achieving enteral autonomy in both stoma and CIC patients –– Data from largest GLP-2 Phase III study to date adds to body of evidence on safety and efficacy of once-weekly apraglutide in adults with SBS-IF –– New details on safety and tolerability to be presented; showing apraglutide to be well tolerated with a safety profile consistent with previously reported apraglutide studies in this patient population – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial,
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Reach OutAccesswire
- Allegations Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Initiates Probe And Invites Investors With Losses To Get In TouchAccesswire
- Claims Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Begins Investigation And Encourages Investors With Losses To Contact ThemAccesswire
- Accusations Against Ironwood Pharmaceuticals, Inc.: The Schall Law Firm Initiates Investigation And Invites Investors With Losses To Reach OutAccesswire
- Ironwood Pharmaceuticals, Inc. Accusations: Schall Law Firm Announces Investigation and Calls for Investors with Losses to ConnectAccesswire
IRWD
Earnings
- 5/9/24 - Miss
IRWD
Sec Filings
- 6/12/24 - Form 4
- 6/10/24 - Form 4
- 6/10/24 - Form 144
- IRWD's page on the SEC website